<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hetem, D J</style></author><author><style face="normal" font="default" size="100%">Derde, L P G</style></author><author><style face="normal" font="default" size="100%">Empel, J</style></author><author><style face="normal" font="default" size="100%">Mroczkowska, A</style></author><author><style face="normal" font="default" size="100%">Orczykowska-Kotyna, M</style></author><author><style face="normal" font="default" size="100%">Kozińska, A</style></author><author><style face="normal" font="default" size="100%">Hryniewicz, W</style></author><author><style face="normal" font="default" size="100%">Goossens, H</style></author><author><style face="normal" font="default" size="100%">Bonten, M J M</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">MOSAR WP3 Study Group</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Molecular epidemiology of MRSA in 13 ICUs from eight European countries.</style></title><secondary-title><style face="normal" font="default" size="100%">J Antimicrob Chemother</style></secondary-title><alt-title><style face="normal" font="default" size="100%">J. Antimicrob. Chemother.</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016 Jan</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">71</style></volume><pages><style face="normal" font="default" size="100%">45-52</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">OBJECTIVES: The European epidemiology of MRSA is changing with the emergence of community-associated MRSA (CA-MRSA) and livestock-associated MRSA (LA-MRSA). In this study, we investigated the molecular epidemiology of MRSA during 2 years in 13 ICUs in France, Greece, Italy, Latvia, Luxemburg, Portugal, Slovenia and Spain.

METHODS: Surveillance cultures for MRSA from nose and wounds were obtained on admission and twice weekly from all patients admitted to an ICU for ≥3 days. The first MRSA isolate per patient was genotyped in a central laboratory by MLST, spa typing, agr typing and SCCmec (sub)typing. Risk factors for patients with an unknown history of MRSA colonization were identified.

RESULTS: Overall, 14 390 ICU patients were screened, of whom 8519 stayed in an ICU for ≥3 days. Overall MRSA admission prevalence was 3.9% and ranged from 1.0% to 7.0% for individual ICUs. Overall MRSA acquisition rate was 2.5/1000 patient days at risk and ranged from 0.2 to 8/1000 patient days at risk per ICU. In total, 557 putative MRSA isolates were submitted to the central laboratory for typing, of which 511 (92%) were confirmed as MRSA. Each country had a distinct epidemiology, with ST8-IVc (UK-EMRSA-2/-6, USA500) being most prevalent, especially in France and Spain, and detected in ICUs in five of eight countries. Seventeen (3%) and three (&lt;1%) isolates were categorized as CA-MRSA and LA-MRSA, respectively. Risk factors for MRSA carriage on ICU admission were age &gt;70 years and hospitalization within 1 year prior to ICU admission.

CONCLUSIONS: The molecular epidemiology of MRSA in 13 European ICUs in eight countries was homogeneous within, but heterogeneous between, countries. CA-MRSA and LA-MRSA genotypes and Panton-Valentine leucocidin-producing isolates were detected sporadically.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/26424737?dopt=Abstract</style></custom1></record></records></xml>